ClinicalTrials.gg
Status unknownNCT02981108Updated Jan 23, 2023Results posted

A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC

A Phase 1/2 interventional study of HS-10296 in Nonsmall Cell Lung Cancer, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Status unknown at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-23.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2022), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
364
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing aumolertinib in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 18 under way, 7 of them phase 3. aumolertinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
7th of 29
364 · median 150
Started
2017
the only one that year
Phase 1/2
Only one
of the 29
Registered
1st of 29
by date
Lead sponsor
8 of 29
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Among the 29 studies testing aumolertinib in Carcinoma, Non-Small-Cell Lung, this one is the 7th largest by enrollment, is the only one that started in 2017, is the only one in phase 1/2, and was the 1st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

13 of the 29 studies testing aumolertinib in Carcinoma, Non-Small-Cell Lung are open now, in 4 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About aumolertinib

aumolertinib: first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing aumolertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a Phase 1/2, open-label, multicenter study of HS-10296 with dose escalation, dose expansion and extension cohorts in locally advanced or metastatic non-small-cell lung cancer (NSCLC) patients who have progressed following prior therapy with an epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor (TKI) agent. The study is designed to evaluate safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of once-daily and orally (PO) administered HS-10296. The overall study design is shown in the flow chart below, which consists of 3 phases: dose escalation, dose expansion and extension cohort.

03

Conditions studied

  • Nonsmall Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated written prior to any study-specific procedures, sampling, and analyses. If a patient declines to participate in any voluntary exploratory research and/or genetic component of the study, there will be no penalty or loss of benefit to the patient and he/she will not be excluded from other aspects of the study.
  2. Age at least 18 years.
  3. Histological or cytological confirmation diagnosis of NSCLC.
  4. Radiological documentation of disease progression while on a previous continuous treatment with an EGFR TKI, e.g., gefitinib or erlotinib. In addition, other may have been given. All patients must have documented radiological progression on the last treatment administered, prior to enrolling in the study.
  5. Patients must fulfill one of the following:

    • Confirmation that the tumor harbors an EGFR mutation known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q) OR must have experienced clinical benefit from EGFR TKI, according to the Jackman criteria (followed by systemic objective progression ( or World Health Organization [WHO]) while on continuous treatment with an EGFR TKI.
  6. For the dose expansion and extension cohorts, patients also must have confirmation of tumor T790M+ mutation status from a sample taken after disease progression on the most recent treatment regimen with an EGFR TKI.

    Prior to entry, a result from the central analysis of the patient's T790M mutation status must be obtained.

  7. World Health Organization (WHO) performance status equal to 0-1 with no deterioration over the previous 2 weeks and a minimum of 12 weeks.
  8. At least 1 lesion that has not previously been irradiated, that has not been chosen for biopsy during the study Screening period,and that can be accurately measured at Baseline as ≥ 10mm in the longest diameter (except lymph nodes which must have short axis ≥ 15mm) with computerized tomography (CT) or magnetic resonance imaging (MRI), which is suitable for accurately repeated measurements.
  9. Females of should be using adequate measures throughout the study, should not be breast feeding at the time of screening, during the study and until 3 months after completion of study, and must have a negative pregnancy test prior to start of dosing if of child-bearing potential or must have evidence of non-child-bearing potential by fulfilling 1 of the following criteria at screening:

    • defined as age more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments.
    • Women under 50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more, following cessation of exogenous hormonal treatments, and with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the post-menopausal range for the laboratory.
    • Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy, but not by tubal ligation.
  10. Male patients should be willing to use barrier contraception (i.e., condoms).
  11. For the dose expansion paired biopsy cohort:

    • Presence of at least 1 non-target lesion suitable for multiple biopsies while on treatment.
  12. For inclusion in optional genetic research, the patient must provide a written informed consent for genetic research.

Exclusion criteria

Exclusion Criteria:

  1. Treatment with any of the following:

    • An EGFR TKI (e.g., erlotinib, gefitinib, or osimertinib) within 8 days or approximately 5 times the half-life of the specific drug, whichever is longer, of the first dose of study treatment. (If sufficient time has not occurred due to scheduling or PK properties, an alternative appropriate wash-out time based on known duration and time to reversibility of drug-related adverse events must be agreed upon by Hansoh and the Investigator).
    • Any cytotoxic chemotherapy, agents, or anticancer drugs for advanced NSCLC used for a previous treatment regimen or clinical study within 14 days of the first dose of study treatment.
    • Major surgery (excluding placement of vascular access) within 4 weeks of the first dose of study treatment.
    • Radiotherapy with a limited field of radiation for palliation within 1 week of the first dose of study treatment, with the exception of patients receiving radiation to more than 30% of the bone marrow or with a wide field of radiation which must be completed within 4 weeks of the first dose of study treatment.
  2. Previously untreated NSCLC patients. To be eligible for this study, patients must have received and progressed on EGFR TKI therapy.
  3. Any unresolved toxicities from prior therapy greater than (CTCAE), Grade 1, at the time of starting study treatment with the exception of alopecia and Grade 2, prior platinum-therapy related neuropathy.
  4. Spinal cord compression or unless asymptomatic, stable, and not requiring for at least 4 weeks prior to start of study treatment.
  5. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension or active bleeding diatheses, which, in the Investigator's opinion, makes it undesirable for the patient to participate in the trial OR which would jeopardize compliance with the protocol such as active infection (e.g., , or [HIV]). Screening for chronic conditions is not required.
  6. Any of the following cardiac criteria:

    • Mean resting interval (QTc) > 470 msec obtained from 3 (ECGs), using the Screening clinic ECG machine and Fridericia's formula for QT interval correction.
    • Any abnormalities in rhythm, conduction, or morphology of the resting ECG (e.g., complete left bundle branch block, third-degree heart block, second-degree heart block, PR interval >250msec).
    • Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval.
  7. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.
  8. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:

    • \< 1.5 x 109/L.
    • count \< 100 x 109/L.
    • \< 90 g/L (\< 9 g/dL).
    • > 2.5 times the (ULN) if no demonstrable liver or > 5 times the ULN in the presence of liver metastases.
    • Aspartate aminotransferase > 2.5 times the ULN if no demonstrable liver metastases or > 5 times the ULN in the presence of liver metastases.
    • Total > 1.5 times the ULN if no liver metastases or > 3 times the ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases.
    • Creatinine > 1.5 times the ULN concurrent with \< 50 mL/min (measured or calculated by the Cockcroft - Gault equation); confirmation of creatinine clearance is only required when creatinine is > 1.5 times the ULN.
  9. nausea, vomiting, or chronic gastrointestinal diseases, inability to swallow the study medication, or previous significant bowel resection that would preclude adequate absorption of HS-10296.
  10. History of to any active or inactive ingredient of HS-10296 or to a drug with a similar chemical structure or class to HS-10296.
  11. Women who are breast feeding.
  12. Involvement in study planning and conduct (i.e., Hansoh staff or staff at the study site).
  13. Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
  14. Any disease or condition that, in the opinion of the Investigator, would compromise the safety of the patient or interfere with study assessments.
  15. The following are considered criteria for exclusion from the exploratory genetic research:

    • Previous allogenic bone marrow transplant.
    • Non-leukocyte leukocyte-depleted whole blood transfusion within 120 days of the date of the genetic sample collection.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
364 participants (actual)

Study arms

  • Experimental
    Escalation Cohort 1

    Oral Once-Daily Administration of HS-10296 55mg

    Drug: HS-10296

  • Experimental
    Escalation Cohort 2

    Oral Once-Daily Administration of HS-10296 110mg

    Drug: HS-10296

  • Experimental
    Escalation Cohort 3

    Oral Once-Daily Administration of HS-10296 220mg

    Drug: HS-10296

  • Experimental
    Escalation Cohort 4

    Oral Once-Daily Administration of HS-10296 260mg

    Drug: HS-10296

  • Experimental
    Expansion Cohort 1

    Oral Once-Daily Administration of HS-10296 55mg

    Drug: HS-10296

  • Experimental
    Expansion Cohort 2

    Oral Once-Daily Administration of HS-10296 110mg

    Drug: HS-10296

  • Experimental
    Expansion Cohort 3

    Oral Once-Daily Administration of HS-10296 220mg

    Drug: HS-10296

  • Experimental
    Phase 2 Extension

    Oral Once-Daily Administration of HS-10296 110mg (RP2D)

    Drug: HS-10296

Interventions

  • HS-10296: 5-, 10-, 40-, and 55-mg tablet, immediate-release formulation. Patients should avoid consumption of food for at least 1 hour prior to and 2 hours post dosing. RP2D is determined at 110 mg QD.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting Toxicity (DLT) Phase I Part

    DLT is defined as one of the following HS-10296 related adverse event (AE) :(1) Hematological toxicity ≥ Grade 4 neutropenia lasting more than 5 days, febrile neutropenia of any duration (absolute neutrophil count \[ANC\]) \< 1.0 × 109/L and fever ≥ 38.5°C), Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with bleeding, any requirement for platelet transfusion, Grade 4 anemia (unexplained by underlying disease); (2)Non-hematological toxicity ≥ CTCAE Grade 3 including Infection (including febrile neutropenia), confirmed prolongation of QT interval corrected with Fridericia's (QTcF) (\> 500 ms absolute or \> 60 ms above Baseline) and cardiac toxicity greater than Grade 3;(3)Any other toxicity that is greater than that at Baseline (clinically significant and/or unacceptable, and judged to be a DLT by the SRC), meets a protocol-defined stopping criteria (i.e., confirmed corneal ulceration), or results in a disruption of dosing schedule of more than 7 days.

    Time frame: 21 days

  2. Overall Response Rate (ORR) Phase II Part

    ORR is defined as the percentage of patients with a complete response (CR) or partial response (PR) that was confirmed at a subsequent scan at least 6 weeks later, as assessed according to RECIST (Response Evaluation Criteria In Solid Tumors Criteria) version 1.1 for target lesions and assessed by CT/MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: From the date of first dose until the date of disease progression or withdrawal from study, approximately 15 months

  3. Incidence and Severity of Adverse Events (AEs) Phase I Part

    An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. An undesirable medical condition can be symptoms (e.g., nausea, chest pain), signs (e.g., tachycardia, enlarged liver), or the abnormal results of an investigation (e.g., laboratory findings, ECG). Any deterioration of the disease under study and associated symptoms or findings should not be regarded as an AE as far as the deterioration can be anticipated. The AE was graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0.

    Time frame: From the screening period to 28 days after treatment completion, approximately 16 months

Secondary outcomes

  1. Area Under the Plasma Concentration Versus Time Curve (AUC) of HS-10296 and HAS-719 From Zero to the 24-Hour Sampling Time (AUC0-24) After Single Dose of HS-10296

    Area under the plasma concentration versus time curve from time zero to the 24-hour sampling time at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-24 was to be calculated according to the mixed log-linear trapezoidal rule.

    Time frame: From pre-dose to 24 hours after single dose on Day 1 of Cycle 0

  2. Elimination Half-life(T1/2) of HS-10296 and HAS-719

    Elimination half-life is the time measured for the concentration to decrease by one half. Half-life calculated by natural log 2 divided by λz.

    Time frame: From pre-dose to 120 hours after single dose on Day 1 of Cycle 0

  3. Css Max of HS-10296 and HAS-719 After Multiple Dose

    Observed maximum plasma concentration (Css max) after multiple dose of HS-10296 and HAS-719

    Time frame: From pre-dose to 21 days after multiple dose on Day 1 of Cycle 2

  4. AUCss of HS-10296 and HAS-719 After Multiple Dose of HS-10296

    Area Under the Plasma Concentration Versus Time Curve at steady state (AUCss) of HS-10296 and HAS-719 after multiple dose of HS-10296

    Time frame: From pre-dose to 21 days after multiple dose on Day 1 of Cycle 2

  5. Overall Response Rate (Phase I Part)

    ORR is defined as the percentage of patients with a complete response (CR) or partial response (PR) that was confirmed at a subsequent scan at least 6 weeks later, as assessed according to RECIST (Response Evaluation Criteria In Solid Tumors Criteria) version 1.1 for target lesions and assessed by CT/MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: From the date of first dose until the date of disease progression or withdrawal from study, approximately 15 months

  6. Progression-free Survival (PFS)

    The PFS is defined as the time from date of first dosing until the date of objective disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death (by any cause in the absence of progression) regardless of whether the patients withdraws from HS-10296 therapy or receives another anti-cancer therapy prior to progression. Progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: From the date of enrollment until the date of disease progression or death from any cause, approximately 15 months

  7. Disease Control Rate (DCR)

    Objective response is assessed by RECIST 1.1 thereby to evaluate disease control rate. The DCR is defined as the proportion of patients with a best overall response of CR, PR, or SD (stable disease).

    Time frame: From the date of first dose until the date of disease progression or withdrawal from study, approximately 15 months

  8. Overall Survival (OS) Phase II Part

    Overall survival will be assessed based on the date of first dose and survival status at the time of analysis. Overall survival is defined as the time from date of first dose until the documentation of death from any cause.

    Time frame: From the date of enrollment until the date of death from any cause, approximately 48 months

  9. Depth of Response (DepOR)

    Depth of Response (DepOR) Only in part II dose-extention phase. DepOR is defined as the percentage change in tumor size, based on longest diameter or reconstructed volume, observed at the lowest point compared with baseline.

    Time frame: From the date of enrollment until the date of disease progression or death, approximately 15 months

  10. Duration of Response (DoR)

    Duration of response (DoR) is defined as the time from the date of first documented response until the date of documented progression or death in the absence of disease progression. The end of response should coincide with the date of progression or death from any cause used for the PFS endpoint. The time of the initial response will be defined as the latest of the dates contributing towards the first visit response of PR or CR. If a patient does not progress following a response, then DoR will be used as the PFS censoring time.

    Time frame: From the date of enrollment until the date of disease progression or death, approximately 18 months

  11. Incidence and Severity of AEs Phase II Part

    An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. An undesirable medical condition can be symptoms (e.g., nausea, chest pain), signs (e.g., tachycardia, enlarged liver), or the abnormal results of an investigation (e.g., laboratory findings, ECG). Any deterioration of the disease under study and associated symptoms or findings should not be regarded as an AE as far as the deterioration can be anticipated. The AE was graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0.

    Time frame: From the screening period to 28 days after treatment completion, approximately 16 months

07

Results

Posted Jan 23, 2023

Participant flow

A total of 364 patients were enrolled at 47 centers in 2 countries.

Participant flow — Overall Study
MilestoneEscalation Cohort 1Escalation Cohort 2Escalation Cohort 3Escalation Cohort 4Expansion Cohort 1Expansion Cohort 2Expansion Cohort 3Phase 2 Extension
Started6686303331244
Completed567621151362
Not completed101091818182

Outcome measures

PrimaryNumber of Participants With Dose Limiting Toxicity (DLT) Phase I Part

DLT is defined as one of the following HS-10296 related adverse event (AE) :(1) Hematological toxicity ≥ Grade 4 neutropenia lasting more than 5 days, febrile neutropenia of any duration (absolute neutrophil count \[ANC\]) \< 1.0 × 109/L and fever ≥ 38.5°C), Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with bleeding, any requirement for platelet transfusion, Grade 4 anemia (unexplained by underlying disease); (2)Non-hematological toxicity ≥ CTCAE Grade 3 including Infection (including febrile neutropenia), confirmed prolongation of QT interval corrected with Fridericia's (QTcF) (\> 500 ms absolute or \> 60 ms above Baseline) and cardiac toxicity greater than Grade 3;(3)Any other toxicity that is greater than that at Baseline (clinically significant and/or unacceptable, and judged to be a DLT by the SRC), meets a protocol-defined stopping criteria (i.e., confirmed corneal ulceration), or results in a disruption of dosing schedule of more than 7 days.

Time frame:
21 days
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicity (DLT) Phase I Part
ParticipantsEscalation Cohort 1Escalation Cohort 2Escalation Cohort 3Escalation Cohort 4
Number of Participants With Dose Limiting Toxicity (DLT) Phase I Part0011
PrimaryOverall Response Rate (ORR) Phase II Part

ORR is defined as the percentage of patients with a complete response (CR) or partial response (PR) that was confirmed at a subsequent scan at least 6 weeks later, as assessed according to RECIST (Response Evaluation Criteria In Solid Tumors Criteria) version 1.1 for target lesions and assessed by CT/MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
From the date of first dose until the date of disease progression or withdrawal from study, approximately 15 months
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) Phase II Part
percentage of participantsPhase 2 Extension
Overall Response Rate (ORR) Phase II Part65.6 (59.2 to 71.5)
PrimaryIncidence and Severity of Adverse Events (AEs) Phase I Part

An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. An undesirable medical condition can be symptoms (e.g., nausea, chest pain), signs (e.g., tachycardia, enlarged liver), or the abnormal results of an investigation (e.g., laboratory findings, ECG). Any deterioration of the disease under study and associated symptoms or findings should not be regarded as an AE as far as the deterioration can be anticipated. The AE was graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0.

Time frame:
From the screening period to 28 days after treatment completion, approximately 16 months
Reported as:
Count of participants · Participants
Incidence and Severity of Adverse Events (AEs) Phase I Part
ParticipantsEscalation Cohort 1Escalation Cohort 2Escalation Cohort 3Escalation Cohort 4Expansion Cohort 1Expansion Cohort 2Expansion Cohort 3
At least one adverse event6686303231
At least one adverse event of Grade 3 or greater11336811
At least one serious adverse event2123563
SecondaryArea Under the Plasma Concentration Versus Time Curve (AUC) of HS-10296 and HAS-719 From Zero to the 24-Hour Sampling Time (AUC0-24) After Single Dose of HS-10296

Area under the plasma concentration versus time curve from time zero to the 24-hour sampling time at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-24 was to be calculated according to the mixed log-linear trapezoidal rule.

Time frame:
From pre-dose to 24 hours after single dose on Day 1 of Cycle 0
Reported as:
Mean · h*ng/mL
Area Under the Plasma Concentration Versus Time Curve (AUC) of HS-10296 and HAS-719 From Zero to the 24-Hour Sampling Time (AUC0-24) After Single Dose of HS-10296
h*ng/mLEscalation Cohort 1Escalation Cohort 2Escalation Cohort 3Escalation Cohort 4
HS-102961740.1175 ± 917.73035250.2364 ± 3345.83488174.4312 ± 8126.70128038.9348 ± 1648.4566
HAS-719298.4934 ± 131.6189696.4536 ± 293.47561152.1150 ± 475.50671564.3829 ± 488.6330
SecondaryElimination Half-life(T1/2) of HS-10296 and HAS-719

Elimination half-life is the time measured for the concentration to decrease by one half. Half-life calculated by natural log 2 divided by λz.

Time frame:
From pre-dose to 120 hours after single dose on Day 1 of Cycle 0
Reported as:
Mean · hours
Elimination Half-life(T1/2) of HS-10296 and HAS-719
hoursEscalation Cohort 1Escalation Cohort 2Escalation Cohort 3Escalation Cohort 4
HS-1029631.29 ± 9.5730.62 ± 9.3435.19 ± 13.8934.81 ± 9.76
HAS-71949.75 ± 10.7055.36 ± 19.9563.75 ± 29.8357.79 ± 13.95
SecondaryCss Max of HS-10296 and HAS-719 After Multiple Dose

Observed maximum plasma concentration (Css max) after multiple dose of HS-10296 and HAS-719

Time frame:
From pre-dose to 21 days after multiple dose on Day 1 of Cycle 2
Reported as:
Mean · ng/mL
Css Max of HS-10296 and HAS-719 After Multiple Dose
ng/mLEscalation Cohort 1Escalation Cohort 2Escalation Cohort 3Escalation Cohort 4Expansion Cohort 1Expansion Cohort 2Expansion Cohort 3Phase 2 Extension
HS-10296164.5000 ± 70.6222352.8333 ± 102.7062762.0000 ± 231.8888765.4000 ± 285.2802197.9308 ± 78.6513413.2751 ± 194.0200552.0635 ± 257.9572352.5111 ± 185.3279
HAS-71955.3500 ± 18.1391118.1333 ± 26.9018276.1667 ± 42.9391338.2000 ± 119.330262.9535 ± 21.4094142.1545 ± 49.4867221.9404 ± 83.6900118.3758 ± 43.3468
SecondaryAUCss of HS-10296 and HAS-719 After Multiple Dose of HS-10296

Area Under the Plasma Concentration Versus Time Curve at steady state (AUCss) of HS-10296 and HAS-719 after multiple dose of HS-10296

Time frame:
From pre-dose to 21 days after multiple dose on Day 1 of Cycle 2
Reported as:
Mean · h*ng/mL
AUCss of HS-10296 and HAS-719 After Multiple Dose of HS-10296
h*ng/mLEscalation Cohort 1Escalation Cohort 2Escalation Cohort 3Escalation Cohort 4Expansion Cohort 1Expansion Cohort 2Expansion Cohort 3Phase 2 Extension
HS-102962488.0953 ± 439.34437000.2498 ± 2832.818011994.8801 ± 3839.416414101.8608 ± 5294.14093550.8674 ± 1451.01737098.0738 ± 2826.122810185.6761 ± 4862.00706602.2491 ± 3482.0499
HAS-719983.7103 ± 201.92672691.7220 ± 677.24075458.2304 ± 659.30788154.0849 ± 1144.06171304.4143 ± 429.12162852.8083 ± 820.18424692.6023 ± 1771.68812467.8527 ± 892.5071
SecondaryOverall Response Rate (Phase I Part)

ORR is defined as the percentage of patients with a complete response (CR) or partial response (PR) that was confirmed at a subsequent scan at least 6 weeks later, as assessed according to RECIST (Response Evaluation Criteria In Solid Tumors Criteria) version 1.1 for target lesions and assessed by CT/MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
From the date of first dose until the date of disease progression or withdrawal from study, approximately 15 months
Reported as:
Number · percentage of participants
Overall Response Rate (Phase I Part)
percentage of participantsEscalation Cohort 1Escalation Cohort 2Escalation Cohort 3Escalation Cohort 4Expansion Cohort 1Expansion Cohort 2Expansion Cohort 3
Overall Response Rate (Phase I Part)50.0 (11.8 to 88.2)66.7 (22.3 to 95.7)37.5 (8.5 to 75.5)16.7 (0.4 to 64.1)60.0 (40.6 to 77.3)54.5 (36.4 to 71.9)41.9 (24.5 to 60.9)
SecondaryProgression-free Survival (PFS)

The PFS is defined as the time from date of first dosing until the date of objective disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death (by any cause in the absence of progression) regardless of whether the patients withdraws from HS-10296 therapy or receives another anti-cancer therapy prior to progression. Progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
From the date of enrollment until the date of disease progression or death from any cause, approximately 15 months
Reported as:
Median · months
Progression-free Survival (PFS)
monthsEscalation Cohort 1Escalation Cohort 2Escalation Cohort 3Escalation Cohort 4Expansion Cohort 1Expansion Cohort 2Expansion Cohort 3Phase 2 Extension
Progression-free Survival (PFS)11.2 (3.0 to NA)7.0 (5.8 to 12.5)5.5 (1.1 to 8.4)3.7 (0.8 to 11.0)9.6 (6.7 to 15.1)13.6 (6.9 to 19.2)11.1 (8.3 to 24.8)12.4 (9.7 to 15.0)
SecondaryDisease Control Rate (DCR)

Objective response is assessed by RECIST 1.1 thereby to evaluate disease control rate. The DCR is defined as the proportion of patients with a best overall response of CR, PR, or SD (stable disease).

Time frame:
From the date of first dose until the date of disease progression or withdrawal from study, approximately 15 months
Reported as:
Number · percentage of participants
Disease Control Rate (DCR)
percentage of participantsEscalation Cohort 1Escalation Cohort 2Escalation Cohort 3Escalation Cohort 4Expansion Cohort 1Expansion Cohort 2Expansion Cohort 3Phase 2 Extension
Disease Control Rate (DCR)100.0 (54.1 to 100.0)100.0 (54.1 to 100.0)75.0 (34.9 to 96.8)50.0 (11.8 to 88.2)83.3 (65.3 to 94.4)97.0 (84.2 to 99.9)93.5 (78.6 to 99.2)93.4 (89.6 to 96.2)
SecondaryOverall Survival (OS) Phase II Part

Overall survival will be assessed based on the date of first dose and survival status at the time of analysis. Overall survival is defined as the time from date of first dose until the documentation of death from any cause.

Time frame:
From the date of enrollment until the date of death from any cause, approximately 48 months
Reported as:
Median · months
Overall Survival (OS) Phase II Part
monthsPhase 2 Extension
Overall Survival (OS) Phase II Part31.5 (25.9 to 35.7)
SecondaryDepth of Response (DepOR)

Depth of Response (DepOR) Only in part II dose-extention phase. DepOR is defined as the percentage change in tumor size, based on longest diameter or reconstructed volume, observed at the lowest point compared with baseline.

Time frame:
From the date of enrollment until the date of disease progression or death, approximately 15 months
Reported as:
Mean · percentage of change from baseline
Depth of Response (DepOR)
percentage of change from baselinePhase 2 Extension
Depth of Response (DepOR)-47.89 ± 22.333
SecondaryDuration of Response (DoR)

Duration of response (DoR) is defined as the time from the date of first documented response until the date of documented progression or death in the absence of disease progression. The end of response should coincide with the date of progression or death from any cause used for the PFS endpoint. The time of the initial response will be defined as the latest of the dates contributing towards the first visit response of PR or CR. If a patient does not progress following a response, then DoR will be used as the PFS censoring time.

Time frame:
From the date of enrollment until the date of disease progression or death, approximately 18 months
Reported as:
Median · months
Duration of Response (DoR)
monthsEscalation Cohort 1Escalation Cohort 2Escalation Cohort 3Escalation Cohort 4Expansion Cohort 1Expansion Cohort 2Expansion Cohort 3Phase 2 Extension
Duration of Response (DoR)13.9 (1.9 to NA)5.6 (4.2 to 9.5)5.6 (4.1 to 7.0)5.5 (NA to NA)8.3 (8.1 to 16.5)12.5 (5.5 to 22.1)22.1 (8.1 to 35.7)15.1 (12.9 to 16.6)
SecondaryIncidence and Severity of AEs Phase II Part

An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. An undesirable medical condition can be symptoms (e.g., nausea, chest pain), signs (e.g., tachycardia, enlarged liver), or the abnormal results of an investigation (e.g., laboratory findings, ECG). Any deterioration of the disease under study and associated symptoms or findings should not be regarded as an AE as far as the deterioration can be anticipated. The AE was graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0.

Time frame:
From the screening period to 28 days after treatment completion, approximately 16 months
Reported as:
Count of participants · Participants
Incidence and Severity of AEs Phase II Part
ParticipantsPhase 2 Extension
At least 1 adverse event219
At least one adverse event of Grade 3 or greater60
At least one serious adverse event30

Adverse events

Collected over Throughout the study, from informed consent until the end of the follow-up period. The follow-up period is defined as 28 ± 3 days after study treatment is discontinued, assessed up to 16 months. Deaths were assessed up to 48 months. Serious and Other (Non-Serious) Adverse Events were assessed up to 16 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Escalation Cohort 10/6 (0%)2/6 (33.3%)6/6 (100%)
Escalation Cohort 20/6 (0%)1/6 (16.7%)6/6 (100%)
Escalation Cohort 30/8 (0%)2/8 (25%)8/8 (100%)
Escalation Cohort 40/6 (0%)3/6 (50%)6/6 (100%)
Expansion Cohort 10/30 (0%)5/30 (16.7%)29/30 (96.7%)
Expansion Cohort 20/33 (0%)6/33 (18.2%)31/33 (93.9%)
Expansion Cohort 30/31 (0%)3/31 (9.7%)29/31 (93.5%)
Phase 2 Extension11/244 (4.5%)30/244 (12.3%)193/244 (79.1%)
Most frequent serious events
Showing 10 of 72
Most frequent serious events
EventEscalation Cohort 1Escalation Cohort 2Escalation Cohort 3Escalation Cohort 4Expansion Cohort 1Expansion Cohort 2Expansion Cohort 3Phase 2 Extension
PneumonitisInfections and infestations1/60/61/81/60/300/330/315/244
SepsisInfections and infestations0/60/60/81/60/300/330/310/244
Urinary tract infectionInfections and infestations1/60/60/80/60/301/330/310/244
PresyncopeNervous system disorders0/60/60/81/60/300/330/311/244
Bowel obstructionGastrointestinal disorders1/60/60/80/60/300/330/310/244
Peripheral swellingGeneral disorders0/60/60/81/60/300/330/310/244
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders0/60/60/81/60/300/330/310/244
Deep vein thrombosisVascular disorders0/61/60/80/60/300/330/312/244
Deep vein thrombosisVascular disorders0/61/60/80/60/300/330/310/244
IleusGastrointestinal disorders1/60/60/80/60/300/330/310/244
Most frequent other events
Showing 10 of 115
Most frequent other events
EventEscalation Cohort 1Escalation Cohort 2Escalation Cohort 3Escalation Cohort 4Expansion Cohort 1Expansion Cohort 2Expansion Cohort 3Phase 2 Extension
NauseaGastrointestinal disorders0/60/62/84/60/304/335/3115/244
ConstipationGastrointestinal disorders2/62/63/80/63/303/332/3120/244
TachycardiaCardiac disorders0/60/61/82/60/300/330/310/244
Abdominal pain upperGastrointestinal disorders1/62/61/80/60/300/330/310/244
DiarrhoeaGastrointestinal disorders2/61/62/80/63/305/337/3111/244
ParonychiaInfections and infestations2/60/61/80/61/300/334/310/244
Upper respiratory tract infectionInfections and infestations2/62/60/80/66/302/333/3132/244
Pain in extremityMusculoskeletal and connective tissue disorders2/60/60/81/63/303/338/310/244
CoughRespiratory, thoracic and mediastinal disorders0/62/61/80/66/304/337/3125/244
RashSkin and subcutaneous tissue disorders0/62/60/80/65/306/336/3130/244

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Escalation Cohort 1Escalation Cohort 2Escalation Cohort 3Escalation Cohort 4Expansion Cohort 1Expansion Cohort 2Expansion Cohort 3Phase 2 ExtensionTotal
<=18 years000000000
Between 18 and 65 years3454221621153228
>=65 years32328171091136
Sex: Female, Male
Sex: Female, Male(Participants)Escalation Cohort 1Escalation Cohort 2Escalation Cohort 3Escalation Cohort 4Expansion Cohort 1Expansion Cohort 2Expansion Cohort 3Phase 2 ExtensionTotal
Female5355192020142219
Male1331111311102145
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Escalation Cohort 1Escalation Cohort 2Escalation Cohort 3Escalation Cohort 4Expansion Cohort 1Expansion Cohort 2Expansion Cohort 3Phase 2 ExtensionTotal
American Indian or Alaska Native000000000
Asian5675293131244358
Native Hawaiian or Other Pacific Islander000001001
Black or African American001000001
White100111004
More than one race000000000
Unknown or Not Reported000000000
Region of Enrollment
Region of Enrollment(participants)Escalation Cohort 1Escalation Cohort 2Escalation Cohort 3Escalation Cohort 4Expansion Cohort 1Expansion Cohort 2Expansion Cohort 3Phase 2 ExtensionTotal
United States102112007
Taiwan565513171855124
China0010161413189233
08

Study locations

10 sites
  • Pacific Cancer Medical Center, Inc.
    Anaheim, California 92801, United States
  • Beverly Hills Cancer Center
    Beverly Hills, California 90211, United States
  • University of California San Diego Medical Center Moores Cancer Center
    San Diego, California 92093, United States
  • University of Colorado-1775 Aurora Court
    Aurora, Colorado 80045, United States
  • Sylvester Comprehensive Cancer Center
    Deerfield Beach, Florida 33442, United States
  • University Cancer & Blood Center, LLC
    Athens, Georgia 30607, United States
  • Baptist Healthcare Systems Inc. Baptist Health Floyd
    New Albany, Indiana 47150, United States
  • Dartmouth-Hitchcock Medical Center
    Hanover, New Hampshire 03755, United States
  • University of Texas Medical Branch at Galveston
    Galveston, Texas 77550, United States
  • MultiCare Institute for Research and Innovation
    Tacoma, Washington 98405, United States
09

References and documents

Publications

  • Yang JC, Camidge DR, Yang CT, Zhou J, Guo R, Chiu CH, Chang GC, Shiah HS, Chen Y, Wang CC, Berz D, Su WC, Yang N, Wang Z, Fang J, Chen J, Nikolinakos P, Lu Y, Pan H, Maniam A, Bazhenova L, Shirai K, Jahanzeb M, Willis M, Masood N, Chowhan N, Hsia TC, Jian H, Lu S. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. J Thorac Oncol. 2020 Dec;15(12):1907-1918. doi: 10.1016/j.jtho.2020.09.001. Epub 2020 Sep 9. PubMed 32916310 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Jan 2019, 19 months.

Results were first posted in Jan 2023, 4 years after primary completion.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's 19 months is below that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2016
First posted
Dec 2, 2016
StartActual
May 8, 2017
Primary completionActual
Jan 5, 2019
CompletionEst.
Mar 31, 2023
Results first posted
Jan 23, 2023
Last update
Jan 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02981108
Responsible party
Sponsor
First posted
Dec 2, 2016
Start date
May 8, 2017
Primary completion
Jan 5, 2019
Completion
Mar 31, 2023 (estimated)
Results posted
Jan 23, 2023
Last update
Jan 23, 2023

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aumolertinib

Start the discussion